
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc's innovative approach in developing targeted therapies for autoimmune disorders using its proprietary precision data analytics platform and extensive expertise presents a compelling growth trajectory. The company's differentiated pipeline, particularly the promising outcomes of its TYK2 inhibitor envudeucitinib (envu), positions it favorably against competitors, suggesting a strong potential for long-term efficacy and market leadership within the class. Additionally, positive trends in cost of goods sold (COGS) further enhance the financial outlook, indicating robust operational efficiency as the company advances its development candidates toward commercialization.
Bears say
Alumis Inc faces multiple risks that negatively impact its stock outlook, particularly regarding the advancement and efficacy of its lead candidates ESK-001 and envu in the autoimmune disorders market. The reported efficacy of competitive therapies, coupled with potential delays in regulatory approvals, further complicates the Company's ability to capture significant market share. Additionally, the current enterprise valuation of approximately $730 million does not adequately reflect the heightened challenges regarding market uptake and the possibility of dilution, suggesting financial instability as the Company navigates these hurdles.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares